Welcome to Lanthio Pharma

About Lanthio Pharma

Lanthio Pharma is a biopharmaceutical company focused on discovering and developing agonistic peptides, with high selectivity for GPCR peptide receptor targets and resistance to peptidase degradation.

PEPTIDES ARE BECOMING INCREASINGLY POPULAR AS THERAPEUTIC DRUGS

Peptide therapeutics are an increasingly important class of drugs. As natural ligands to many targets, they can combine agonistic activity with low toxicity risk. Importantly they can be applied to targets, where small molecules or antibody-based drugs are not an option.

CREATING TARGET SPECIFIC AGONISTIC PEPTIDES

A peptide can have different structural conformations. One conformation is often optimal for specific receptor binding. Lanthio Pharma's technology can be used to identify peptides which are selective for a specific target and to stabilize them in their optimal structural conformation for receptor binding. In this way we have already identified several selective and highly active agonistic peptides for GPCR peptide targets. This target selectivity can open up exciting new therapeutic applications around known targets.

PROTECTION AGAINST DEGRADATION BY PEPTIDASES

A drawback of using peptides therapeutically can be their rapid degradation by peptidases in the body. Lanthio Pharma's technology not only stabilizes peptides in their optimal target binding conformation, the introduction of lanthionines also provides strong protection against peptidase degradation. As such, our peptides are likely to have good "drug-like" properties.